These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38221739)

  • 1. Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study.
    Schultz BG; Bullano M; Paratane D; Rajagopalan K
    Transpl Infect Dis; 2024 Apr; 26(2):e14216. PubMed ID: 38221739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
    Schultz BG; Kotton CN; Jutlla G; Ressa R; de Lacey T; Chowdhury E; Bo T; Fenu E; Gelone DK; Poirrier JE; Amorosi SL
    J Med Virol; 2024 Apr; 96(4):e29609. PubMed ID: 38647051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization of maribavir versus investigator-assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial.
    Hirji I; Cocks K; Moreno-Koehler A; Sundberg A
    Transpl Infect Dis; 2023 Jun; 25(3):e14064. PubMed ID: 37154528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
    Avery RK; Alain S; Alexander BD; Blumberg EA; Chemaly RF; Cordonnier C; Duarte RF; Florescu DF; Kamar N; Kumar D; Maertens J; Marty FM; Papanicolaou GA; Silveira FP; Witzke O; Wu J; Sundberg AK; Fournier M;
    Clin Infect Dis; 2022 Sep; 75(4):690-701. PubMed ID: 34864943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
    Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
    J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
    Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
    J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
    Monday LM; Keri V; Chandrasekar PH
    Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Perspectives on Antimicrobial Agents: Maribavir.
    Halpern-Cohen V; Blumberg EA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.
    Kleiboeker HL; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Rice JP; Saddler CM; Smith JA; Jorgenson MR
    Ann Pharmacother; 2023 May; 57(5):597-608. PubMed ID: 36003036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource Use and Financial Impact of Oral Step-Down Therapy for Resistant Cytomegalovirus in Solid Organ Transplant Recipients.
    Kleiboeker H; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA; Jorgenson MR
    Transplant Proc; 2024 Mar; 56(2):434-439. PubMed ID: 38355369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature.
    Corcione S; Lupia T; Vita D; Sidoti F; Zanotto E; Solidoro P; Biancone L; Costa C; Balagna R; De Rosa FG
    Transplant Rev (Orlando); 2024 Dec; 38(4):100873. PubMed ID: 39178643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
    Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
    BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
    Drugs R D; 2007; 8(3):188-92. PubMed ID: 17472414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.